{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:43:21Z","timestamp":1793832201115,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC3602500"],"award-info":[{"award-number":["2022YFC3602500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013Glucose Cotransporter-2 Inhibitor (SGLT2i) is a novel oral drug for treating type 2 diabetes mellitus (T2DM) with demonstrated cardiovascular benefits. Previous studies in apolipoprotein E knockout mice have shown that SGLT2i is associated with attenuated progression of atherosclerosis. However, whether this effect extends to T2DM patients with coronary atherosclerosis in real-world settings remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this longitudinal cohort study using coronary computed tomography angiography (CCTA), T2DM patients who underwent\u2009\u2265\u20092 CCTA examinations at our center between 2019 and 2022 were screened. Eligible patients had multiple study plaques, defined as non-obstructive stenosis at baseline and not intervened during serial CCTAs. Exclusion criteria included a CCTA time interval\u2009&lt;\u200912 months, prior SGLT2i treatment, or initiation\/discontinuation of SGLT2i during serial CCTAs. Plaque volume (PV) and percent atheroma volume (PAV) were measured for each study plaque using CCTA plaque analysis software. Patients and plaques were categorized based on SGLT2i therapy and compared using a 1:1 propensity score matching (PSM) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 236 patients (mean age 60.5\u2009\u00b1\u20099.5 years; 69.1% male) with 435 study plaques (diameter stenosis\u2009\u2265\u200950%, 31.7%). Following SGLT2i treatment for a median duration of 14.6 (interquartile range: 13.0, 20.0) months, overall, non-calcified, and low-attenuation PV and PAV were significantly decreased, while calcified PV and PAV were increased (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Meanwhile, reductions in overall PV, non-calcified PV, overall PAV, and non-calcified PAV were significantly greater in SGLT2i-treated compared to non-SGLT2i-treated plaques (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). PSM analysis showed that SGLT2i treatment was associated with higher reductions in overall PV (\u2212\u00a011.77 mm\n                      <jats:sup>3<\/jats:sup>\n                      vs. 4.33 mm\n                      <jats:sup>3<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), non-calcified PV (\u2212\u00a016.96 mm\n                      <jats:sup>3<\/jats:sup>\n                      vs. \u2212\u00a01.81 mm\n                      <jats:sup>3<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017), overall PAV (\u2212\u00a02.83% vs. 3.36%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and non-calcified PAV (\u2212\u00a04.60% vs. 0.70%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). These findings remained consistent when assessing annual changes in overall and compositional PV and PAV. Multivariate regression models demonstrated that SGLT2i therapy was associated with attenuated progression of overall or non-calcified PV or PAV, even after adjusting for cardiovascular risk factors, medications, and baseline overall or non-calcified PV or PAV, respectively (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The effect of SGLT2i on attenuating non-calcified plaque progression was consistent across subgroups (all\n                      <jats:italic>p<\/jats:italic>\n                      for interaction\u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this longitudinal CCTA cohort of T2DM patients, SGLT2i therapy markedly regressed coronary overall PV and PAV, mainly result from a significant reduction in non-calcified plaque.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02368-y","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:03:29Z","timestamp":1721646209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Longitudinal assessment of coronary plaque regression related to sodium\u2013glucose cotransporter-2 inhibitor using coronary computed tomography angiography"],"prefix":"10.1186","volume":"23","author":[{"given":"Tianhao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"2368_CR1","volume-title":"IDF Diabetes Atlas","author":"DJ Magliano","year":"2021","unstructured":"Magliano DJ, Boyko EJDA. IDF Diabetes Atlas. Brussels: International Diabetes Federation; 2021."},{"issue":"1","key":"2368_CR2","first-page":"17","volume":"12","author":"C Kalofoutis","year":"2007","unstructured":"Kalofoutis C, Piperi C, Kalofoutis A, Harris F, Phoenix D, Singh J. Type II diabetes mellitus and cardiovascular risk factors: current therapeutic approaches. Exp Clin Cardiol. 2007;12(1):17\u201328.","journal-title":"Exp Clin Cardiol"},{"issue":"5","key":"2368_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1753-0407.12644","volume":"10","author":"AM Carracher","year":"2018","unstructured":"Carracher AM, Marathe PH, Close KL. International diabetes federation 2017. J Diabetes. 2018;10(5):353\u20136.","journal-title":"J Diabetes"},{"issue":"4","key":"2368_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4103\/2230-8210.183480","volume":"20","author":"A Chawla","year":"2016","unstructured":"Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab. 2016;20(4):546\u201351.","journal-title":"Indian J Endocrinol Metab"},{"issue":"9933","key":"2368_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(14)60794-7","volume":"383","author":"RR Holman","year":"2014","unstructured":"Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383(9933):2008\u201317.","journal-title":"Lancet"},{"issue":"1S","key":"2368_CR6","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.amjcard.2017.05.009","volume":"120","author":"J Thrasher","year":"2017","unstructured":"Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Cardiol. 2017;120(1S):S4\u201316.","journal-title":"Am J Cardiol"},{"issue":"22","key":"2368_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med. 2015;373(22):2117\u201328.","journal-title":"New Engl J Med"},{"issue":"2","key":"2368_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. New Engl J Med. 2021;384(2):129\u201339.","journal-title":"New Engl J Med"},{"issue":"7","key":"2368_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med. 2017;377(7):644\u201357.","journal-title":"New Engl J Med"},{"issue":"4","key":"2368_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2019;380(4):347\u201357.","journal-title":"New Engl J Med"},{"issue":"24","key":"2368_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink H, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"New Engl J Med"},{"issue":"15","key":"2368_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, et al. Cardiovascular outcomes with Ertugliflozin in Type 2 diabetes. New Engl J Med. 2020;383(15):1425\u201335.","journal-title":"New Engl J Med"},{"issue":"2","key":"2368_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney D, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a Meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"39","key":"2368_CR14","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"2","key":"2368_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","volume":"60","author":"JH Han","year":"2017","unstructured":"Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, Choi SH, Jang HC, Lee HS, Park KS, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (\u2212\/\u2212) mice fed a western diet. Diabetologia. 2017;60(2):364\u201376.","journal-title":"Diabetologia"},{"issue":"1","key":"2368_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","volume":"17","author":"N Nasiri-Ansari","year":"2018","unstructured":"Nasiri-Ansari N, Dimitriadis GK, Agrogiannis G, Perrea D, Kostakis ID, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17(1):106.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2368_CR17","doi-asserted-by":"publisher","first-page":"e022761","DOI":"10.1161\/JAHA.121.022761","volume":"11","author":"YC Chen","year":"2022","unstructured":"Chen YC, Jandeleit-Dahm K, Peter K. Sodium\u2013glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced atherosclerotic plaque instability. J Am Heart Assoc. 2022;11(1):e022761.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2368_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jcmg.2022.10.017","volume":"16","author":"SE van Rosendael","year":"2023","unstructured":"van Rosendael SE, van den Hoogen IJ, Lin FY, Andreini D, Al-Mallah MH, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Conte E, et al. Clinical and coronary plaque predictors of atherosclerotic nonresponse to statin therapy. Jacc-Cardiovasc Imag. 2023;16(4):495\u2013504.","journal-title":"Jacc-Cardiovasc Imag"},{"issue":"6","key":"2368_CR19","first-page":"435","volume":"10","author":"S Abbara","year":"2016","unstructured":"Abbara S, Blanke P, Maroules CD, Cheezum M, Choi AD, Han BK, Marwan M, Naoum C, Norgaard BL, Rubinshtein R, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the society of Cardiovascular computed Tomography Guidelines Committee: endorsed by the North American Society for Cardiovascular Imaging (NASCI). J Cardiovasc Comput. 2016;10(6):435\u201349.","journal-title":"J Cardiovasc Comput"},{"key":"2368_CR20","doi-asserted-by":"crossref","unstructured":"Guo B, Jiang M, Guo X, Tang C, Zhong J, Lu M, Liu C, Zhang X, Qiao H, Zhou F et al. Diagnostic and prognostic performance of artificial intelligence-based fully-automated on-site CT-FFR in patients with CAD. Sci Bull 2024;69:1472","DOI":"10.1016\/j.scib.2024.03.053"},{"issue":"2","key":"2368_CR21","first-page":"93","volume":"15","author":"LJ Shaw","year":"2021","unstructured":"Shaw LJ, Blankstein R, Bax JJ, Ferencik M, Bittencourt MS, Min JK, Berman DS, Leipsic J, Villines TC, Dey D, et al. Society of cardiovascular computed tomography\/North American Society of cardiovascular imaging\u2014expert consensus document on coronary CT imaging of atherosclerotic plaque. J Cardiovasc Comput. 2021;15(2):93\u2013109.","journal-title":"J Cardiovasc Comput"},{"issue":"2","key":"2368_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1148\/radiol.10100681","volume":"257","author":"D Dey","year":"2010","unstructured":"Dey D, Schepis T, Marwan M, Slomka PJ, Berman DS, Achenbach S. Automated three-dimensional quantification of noncalcified coronary plaque from coronary CT angiography: comparison with intravascular US. Radiology. 2010;257(2):516\u201322.","journal-title":"Radiology"},{"issue":"2","key":"2368_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1148\/radiol.2017170127","volume":"286","author":"M Sheahan","year":"2018","unstructured":"Sheahan M, Ma X, Paik D, Obuchowski NA, St PS, Newman WR, Rae G, Perlman ES, Rosol M, Keith JJ, et al. Atherosclerotic plaque tissue: noninvasive quantitative assessment of characteristics with Software-aided measurements from conventional CT angiography. Radiology. 2018;286(2):622\u201331.","journal-title":"Radiology"},{"issue":"2","key":"2368_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1001\/jamacardio.2022.3926","volume":"8","author":"PH Stone","year":"2023","unstructured":"Stone PH, Libby P, Boden WE. Fundamental pathobiology of coronary atherosclerosis and clinical implications for chronic ischemic heart Disease Management-the Plaque hypothesis: a narrative review. JAMA Cardiol. 2023;8(2):192\u2013201.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"2368_CR25","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamacardio.2021.3055","volume":"6","author":"AR van Rosendael","year":"2021","unstructured":"van Rosendael AR, van den Hoogen IJ, Gianni U, Ma X, Tantawy SW, Bax AM, Lu Y, Andreini D, Al-Mallah MH, Budoff MJ, et al. Association of Statin Treatment with Progression of Coronary atherosclerotic plaque composition. JAMA Cardiol. 2021;6(11):1257\u201366.","journal-title":"JAMA Cardiol"},{"key":"2368_CR26","doi-asserted-by":"crossref","unstructured":"Hirai K, Imamura S, Hirai A, Ookawara S, Morishita Y. Effect of Evolocumab on vulnerable coronary plaques: a serial coronary computed Tomography Angiography Study. J Clin Med 2020, 9(10):3338","DOI":"10.3390\/jcm9103338"},{"issue":"2 Pt 2","key":"2368_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","volume":"11","author":"K Vaidya","year":"2018","unstructured":"Vaidya K, Arnott C, Martinez GJ, Ng B, McCormack S, Sullivan DR, Celermajer DS, Patel S. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. JACC-Cardiovasc Imag. 2018;11(2 Pt 2):305\u201316.","journal-title":"JACC-Cardiovasc Imag"},{"issue":"40","key":"2368_CR28","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","volume":"41","author":"MJ Budoff","year":"2020","unstructured":"Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925\u201332.","journal-title":"Eur Heart J"},{"issue":"2","key":"2368_CR29","first-page":"142","volume":"13","author":"KB Won","year":"2019","unstructured":"Won KB, Lee SE, Lee BK, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, et al. Longitudinal assessment of coronary plaque volume change related to glycemic status using serial coronary computed tomography angiography: a PARADIGM (progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging) substudy. J Cardiovasc Comput. 2019;13(2):142\u20137.","journal-title":"J Cardiovasc Comput"},{"issue":"1","key":"2368_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-020-01079-4","volume":"19","author":"N Katakami","year":"2020","unstructured":"Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;19(1):110.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2368_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-023-01879-4","volume":"22","author":"N Katakami","year":"2023","unstructured":"Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Kurozumi A, Hatazaki M, Kaneto H, Osonoi T, et al. Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial. Cardiovasc Diabetol. 2023;22(1):143.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2368_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12933-022-01451-6","volume":"21","author":"N Katakami","year":"2022","unstructured":"Katakami N, Mita T, Maeda N, Sato Y, Watada H, Shimomura I. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial. Cardiovasc Diabetol. 2022;21(1):19.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2368_CR33","first-page":"120","volume":"17","author":"C Thomsen","year":"2016","unstructured":"Thomsen C, Abdulla J. Characteristics of high-risk coronary plaques identified by computed tomographic angiography and associated prognosis: a systematic review and meta-analysis. Eur Heart J-CARD Img. 2016;17(2):120\u20139.","journal-title":"Eur Heart J-CARD Img"},{"issue":"18","key":"2368_CR34","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1161\/CIRCULATIONAHA.119.044720","volume":"141","author":"MC Williams","year":"2020","unstructured":"Williams MC, Kwiecinski J, Doris M, McElhinney P, D\u2019Souza MS, Cadet S, Adamson PD, Moss AJ, Alam S, Hunter A, et al. Low-attenuation Noncalcified Plaque on Coronary computed Tomography Angiography predicts myocardial infarction: results from the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation. 2020;141(18):1452\u201362.","journal-title":"Circulation"},{"issue":"1","key":"2368_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","volume":"22","author":"C Sardu","year":"2023","unstructured":"Sardu C, Trotta MC, Sasso FC, Sacra C, Carpinella G, Mauro C, Minicucci F, Calabro P, D\u2019 AM, D\u2019 AF, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22(1):80.","journal-title":"Cardiovasc Diabetol"},{"key":"2368_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.amjcard.2023.12.056","volume":"214","author":"A Kurozumi","year":"2024","unstructured":"Kurozumi A, Shishido K, Yamashita T, Sato D, Uchida S, Koyama E, Tamaki Y, Hayashi T, Miyashita H, Yokoyama H, et al. Sodium\u2013glucose Cotransporter-2 inhibitors stabilize coronary plaques in acute coronary syndrome with diabetes mellitus. Am J Cardiol. 2024;214:47\u201354.","journal-title":"Am J Cardiol"},{"issue":"11","key":"2368_CR37","doi-asserted-by":"publisher","first-page":"e0143396","DOI":"10.1371\/journal.pone.0143396","volume":"10","author":"M Terasaki","year":"2015","unstructured":"Terasaki M, Hiromura M, Mori Y, Kohashi K, Nagashima M, Kushima H, Watanabe T, Hirano T. Amelioration of hyperglycemia with a sodium\u2013glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS ONE. 2015;10(11):e0143396.","journal-title":"PLoS ONE"},{"issue":"1","key":"2368_CR38","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1038\/s41598-019-54224-9","volume":"9","author":"J Pennig","year":"2019","unstructured":"Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Funer L, Hardtner C, Stachon P, Wolf D, Hilgendorf I, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep-UK. 2019;9(1):17937.","journal-title":"Sci Rep-UK"},{"issue":"5","key":"2368_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4070\/kcj.2019.0296","volume":"50","author":"SG Lee","year":"2020","unstructured":"Lee SG, Lee SJ, Lee JJ, Kim JS, Lee OH, Kim CK, Kim D, Lee YH, Oh J, Park S, et al. Anti-inflammatory effect for atherosclerosis progression by sodium\u2013glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model. Korean Circ J. 2020;50(5):443\u201357.","journal-title":"Korean Circ J"},{"key":"2368_CR40","doi-asserted-by":"publisher","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","volume":"875","author":"B Ganbaatar","year":"2020","unstructured":"Ganbaatar B, Fukuda D, Shinohara M, Yagi S, Kusunose K, Yamada H, Soeki T, Hirata KI, Sata M. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020;875:173040.","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"2368_CR41","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1093\/cvr\/cvad119","volume":"119","author":"A Chen","year":"2023","unstructured":"Chen A, Lan Z, Li L, Xie L, Liu X, Yang X, Wang S, Liang Q, Dong Q, Feng L, et al. Sodium\u2013glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome. Cardiovasc Res. 2023;119(13):2368\u201381.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2368_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41401-023-01217-0","volume":"45","author":"XX Li","year":"2024","unstructured":"Li XX, Chen ZD, Sun XJ, Yang YQ, Jin H, Liu NF. Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation. Acta Pharmacol Sin. 2024;45(4):751\u201364.","journal-title":"Acta Pharmacol Sin"},{"key":"2368_CR43","doi-asserted-by":"publisher","first-page":"103183","DOI":"10.1016\/j.redox.2024.103183","volume":"73","author":"S Wu","year":"2024","unstructured":"Wu S, Luo X, Chen Y, Wang Z, Liu X, Sun N, Zhao J, Luo W, Zhang J, Tong X, et al. Sodium\u2013glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming. Redox Biol. 2024;73:103183.","journal-title":"Redox Biol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02368-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02368-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02368-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T12:03:28Z","timestamp":1721649808000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02368-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2368"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02368-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4422484\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of Beijing Anzhen Hospital. Informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"If the manuscript is accepted, we approve it for publication in Cardiovascular Diabetology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}